<DOC>
	<DOCNO>NCT01384123</DOCNO>
	<brief_summary>Sarcoidosis heterogeneous multisystem disorder unknown etiology often present bilateral hilar lymphadenopathy , pulmonary infiltration ocular skin lesion . In addition possible change force vital capacity ( FVC ) carbon monoxide transfer factor ( TLCO ) , high prevalence clinical depression , reduce health status exercise intolerance observe patient sarcoidosis . Reduced health status relate decrease pulmonary function , depressive symptom , respiratory muscle weakness . Exercise capacity believe limited dyspnea , insufficient heart rate response , decrease arterial oxygen tension exercise , excessive inefficient ventilation respiratory muscle weakness . In past , exercise capacity show limited skeletal muscle weakness patient chronic pulmonary cardiac disease . 67 % sarcoidosis patient study Miller et al terminate peak exercise test due `` leg complaint '' . Skeletal muscle weakness therefore still assume present patient sarcoidosis . Treatment oral corticosteroid , clinical symptom depression , myositis , self-reported complaint fatigue high circulating level tumour necrosis factor-α ( TNF-α ) present patient sarcoidosis affect skeletal muscle force exercise capacity . Additionally , low level circulate insulin-like growth factor I ( IGF-I ) , induce high level TNF-α , high circulating level interleukin ( IL ) -6 IL-8 ( CXCL8 ) associate skeletal muscle weakness . These interleukin part current concept immunopathogenesis sarcoidosis16 may raise patient stable sarcoidosis . Recent study show pulmonary rehabilitation program lead improve health status anxiety among patient chronic obstructive lung disease .However , study evaluate role pulmonary rehabilitation among patient sarcoidosis .</brief_summary>
	<brief_title>Rehabilitation Pulmonary Sarcoidosis : Prospective Study</brief_title>
	<detailed_description />
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<criteria>Stable pulmonary sarcoidosis change medication last 3 month . Any significant pulmonary and\or comorbidity affect exercise tolerance . Chronic steroid treatment 5 mg/day . Previous lung surgery . Advanced heart failure ( NYHA IIIIV ) Malignancy last 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>stable pulmonary sarcoidosis change medication last 3 months/</keyword>
</DOC>